Consecutive clinical isolates of Escherichia coli (n= 87) and Klebsiella pneumoniae (n= 25)
with reduced susceptibilities to oxyimino-cephalosporins (MICs> 1 mg/liter) from 18 …

Using a set of 33 well-defined extended-spectrum beta-lactamase (ESBL)-producing strains
of Escherichia coli and Klebsiella pneumoniae, we compared three screening methods for …

Extended-spectrum beta-lactamase (ESBL) producing Escherichia coli and Klebsiella spp.
isolates are spreading and becoming an increasing problem concerning treatment …

Abstract Background: Most Gram-negative community-acquired and nosocomial infections
are caused by Escherichia coli and Klebsiella pneumoniae, among which increasing …

Resistance to contemporary broad-spectrum beta-lactams, mediated by extended-spectrum
beta-lactamase (ESBL) enzymes, is an increasing problem worldwide. The Etest (AB …

Escherichia coli and Klebsiella spp. were screened for ESBL based on routine susceptibility
testing results. Isolates with intermediate or resistant susceptibilities for extended spectrum …

The frequency of occurrence of ESBL-producing clinical strains varies widely in distinct
geographic areas. The objective of this study was to describe the frequency of occurrence …

Forty clinical isolates of Escherichia coli and 141 isolates of Klebsiella pneumoniae that
either transferred ceftazidime resistance or showed sulbactam enhancement of oxyimino …

The genetic characteristics and molecular epidemiology of extended-spectrum β-lactamases
(ESBLs) among Escherichia coli isolates were investigated at a general hospital and its …

We conducted a survey of extended-spectrum β-lactamases (ESBLs) among 16 805
Escherichia coli and 9794 Klebsiella pneumoniae clinical isolates recovered from 196 …